HOME >> BIOLOGY >> NEWS
New method for reading DNA sheds light on basis of cell identity

As a fertilized egg develops into a full grown adult, mammalian cells make many crucial decisions closing doors of opportunity as they adopt careers as liver cells, skin cells, or neurons. One of the most fundamental mysteries in biomedicine is how cells make such different career decisions despite having exactly the same DNA. By using a new kind of genomic technology, a new study unveils a special code not within DNA, but within the so-called chromatin proteins surrounding it that could unlock these mysterious choices underlying cell identity.

A research team led by scientists at the Broad Institute of Harvard and MIT and the Massachusetts General Hospital has created genome-wide chromatin maps for embryonic stem (ES) cells and two cell types derived from them, by applying a powerful new technology for sequencing DNA. The work, published in the July 1st advance online edition of Nature, provides a framework for mapping the complete chromatin landscape of almost any kind of cell. One of the most surprising findings suggests that cells contain an explicit chromatin-based code that reveals the developmental choices they have already made as well as those decisions that lie ahead.

Unraveling the mysteries of chromatin holds great promise for understanding how cells in the body with nearly identical DNA assume such different forms and functions, said co-senior author Bradley Bernstein, an associate member at the Broad Institute and an assistant professor at Massachusetts General Hospital and Harvard Medical School. By applying a new technology for sequencing DNA, we have been able to look across the genome at chromatin, with greater resolution and efficiency than ever before.

Chromatin proteins are more than just packing material for the genome. By virtue of different chemical groups fastened to them, these proteins influence which parts of the double helix are open or not to the cellular machinery, thus controlling which genes
'"/>

Contact: Nicole Davis
ndavis@broad.mit.edu
617-258-0952
Broad Institute of MIT and Harvard
1-Jul-2007


Page: 1 2 3

Related biology news :

1. Cost-effective method for gene silencing is featured in Cold Spring Harbor Protocols
2. A new method of adult stem cell growth efficacious in treatment of disorders of the cornea
3. Purdue-IU researchers explore new method for early disease diagnosis
4. Sequencing method yields fuller picture
5. New imaging method clarifies nutrient cycle
6. Researchers discover method for identifying how cancer evades the immune system
7. Bioinformatics-related methods are featured in Cold Spring Harbor Protocols
8. Nanoparticles hitchhike on red blood cells: a potential new method for drug delivery
9. Rutgers, Penn researchers capture research dollars to improve prostate cancer diagnostic methods
10. Developer of new method for treating bone defects wins WPI Entrepreneurship Award
11. New screening method to help find better biofuel crops

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New method for reading DNA sheds light basis cell identity

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: